CELZ — Creative Medical Technology Holdings Income Statement
0.000.00%
- $5.17m
- -$0.77m
- $0.01m
- 29
- 20
- 36
- 18
Annual income statement for Creative Medical Technology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.165 | 0.088 | 0.089 | 0.009 | 0.011 |
Cost of Revenue | |||||
Gross Profit | 0.114 | 0.04 | 0.06 | 0.005 | 0.007 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.28 | 2.63 | 10.3 | 5.63 | 5.75 |
Operating Profit | -1.11 | -2.54 | -10.2 | -5.62 | -5.74 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -36.3 | 19.2 | -10.1 | -5.29 | -5.49 |
Provision for Income Taxes | |||||
Net Income After Taxes | -36.3 | 19.2 | -10.1 | -5.29 | -5.49 |
Net Income Before Extraordinary Items | |||||
Net Income | -36.3 | 19.2 | -10.1 | -5.29 | -5.49 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -36.3 | 19.2 | -10.1 | -5.29 | -5.49 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -627 | 57.3 | -9.28 | -3.76 | -3.71 |